** Shares of drugmaker BridgeBio Pharma BBIO.O rise 7.08% to $39 after market
** Co posts Q1 Attruby sales of $36.7 million, beating estimates of $13.10 million, according to data compiled by LSEG
** Attruby is used to treat adults with transthyretin amyloid cardiomyopathy (ATTR-CM), in which faulty transthyretin proteins accumulate in the heart and can cause the organ to fail
** As of April 25, 2,072 unique patient prescriptions for Attruby have been written by 756 healthcare providers since FDA approval in November 2024
** Attruby launch continues to be strong so far and has raised market expectations — BMO Capital Markets
** Stock up ~32% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。